Claudin7 and moesin in endometrial Adenocarcinoma; a retrospective study of 265 patients

BMC Research Notes

Song Liu⁴  Tanja Pejovic³  Peter J Frederick¹  Shashikant Lele¹  Dan Wang⁴  Paulette Mhawech-Fauceglia² 

[1] Department of Gynecologic Oncology at Roswell Park Cancer Institute, Buffalo, NY, USA;University of Southern California, Los Angeles, CA, USA;Department of Gynecology-Oncology Surgery at Oregon Health and Science, Portland, Oregon, USA;Department of Biostatistics, Roswell Park Cancer Institute, Buffalo, NY, USA

关键词: Clinical outcome;    Endometrial adenocarcinoma;    Claudin7;    Moesin;   

Others  :  1166720
DOI  :  10.1186/1756-0500-5-65

 received in 2011-11-09, accepted in 2012-01-24,  发布年份 2012

【 摘 要 】

Background

Metastasis is the main cause of death in cancer and is a multistep process. Moesin (MSN), a member of the ezrin-rdixin-moesin family and Claudin7 (CLDN7), a tight junction protein, both play a role in tumor cell metastasis. Previously, we found an over-expression of MSN and under-expression of CLDN7 at the mRNA level in uterine serous carcinoma in comparison to uterine endometrioid adenocarcinoma. The purpose of this study is to determine the protein expression of MSN and CLDN7 in endometrial cancer (EC) and to evaluate their prognostic value. Two hundred sixty-five patients with EC were retrieved from the archives. MSN and CLDN7 immunostaining were performed on the tissue paraffin sections. The expression of each antibody was reported and then correlated with clinicopathological prognostic factors including age, tumor grade, tumor stage, lympho-vascular involvement, depth of myometrial invasion, overall survival (OS), disease free survival (DFS) and death of disease (DOD).

Results

MSN and CLDN were expressed in 46% and 52% of overall cases. We observed an association between MSN⁺ staining and tumor grade, and serous and clear cell carcinoma subtypes (p < 0.001 each). There was an association between CLDN7⁺ staining and low tumor grade and endometrioid adenocarcinoma subtype (p < 0.001 and 0.001 respectively). However, no association between MSN and CLDN7 expression and outcome including OS, DOD, and DFS was found.

Conclusion

A significant prognostic value of MSN and CLDN7 in predicting disease outcomes in patients with EC was not demonstrated. Nevertheless, the high percentage of EC cases with MSN and CLDN7 immunoexpression, and their association with tumor grade and subtypes, suggests that these proteins might play a role in tumorigenesis of endometrial adenocarcinomas. Future studies are needed to shed light on their mechanistic properties in EC cells.

【 授权许可】

   
2012 Mhawech-Fauceglia et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-249.
• [2]Kitchener HC, Trimble EL: Endometrial cancer state of the science meeting. Int J Gynecol Cancer 2009, 19:134-140.
• [3]Naumann RW: Uterine papillary serous carcinoma: state of the state. Curr Oncol Rep 2008, 10:505-511.
• [4]Benito V, Lubrano A, Arencibia O, Alvarez EE, León L, Medina N, Falcón JM, Falcón O: Pure papillary serous tumors of the endometrium: a clinicopathological analysis of 61 cases from a single institution. Int J Gynecol Cancer 2009, 19:1364-1369.
• [5]Mhawech-Fauceglia P, Wang D, Kesterson J, Clark K, Monhollen L, Odunsi K, Lele S, Liu S: Microarray analysis reveals distinct gene expression profiles among different tumor histology, stage and disease outcomes in endometrial adenocarcinoma. PLoS One 2010, 5:e15415.
• [6]Mhawech-Fauceglia P, Wang D, Wang D, Syriac S, Kesterson J, Clark K, Frederick P, Lele S, Liu S: Gene Expression Profiles in Stage I Uterine Serous Carcinoma in Comparison to Grade 3 and Grade 1 Stage I Endometrioid Adenocarcinoma. PLoS One 2011, 6:e18066.
• [7]Sato N, Funayama N, Nagafuchi A, Yonemura S, Tsukita S, Tsukita S: A gene family consisting of ezrin, radixin and moesin. Its specific localization at actin filament/plasma membrane association sites. J Cell Sci 1992, 103:131-143.
• [8]Arpin M, Chirivino D, Naba A, Zwaenepoel I: Emerging role of ERM proteins in cell adhesion and migration. Cell Adh Migr 2011, 1(5):199-206.
• [9]Lallemand D, Arpin M: moesin/ezrin: a specific role in cell metastasis? Pigment Cell Melanoma Res 2010, 23:6-7.
• [10]Louvet-Vallee S: ERM proteins: From cellular architecture to cell signaling. Biology of the cell 2000, 92:305-316.
• [11]Hunter KW: Ezrin, a key component in tumor metastasis. Trends Mol Med 2004, 10:201-204.
• [12]Abiatari I, Esposito I, Oliveira TD, Felix K, Xin H, Penzel R, Giese T, Friess H, Kleeff J: Moesin-dependent cytoskeleton remodelling is associated with an anaplastic phenotype of pancreatic cancer. J Cell Mol Med 2010, 14:1166-1179.
• [13]Ou-Yang M, Liu H-R, Zhang Y, Zhu X, Yang Q: ERM stable knockdown by siRNA reduced in vitro migration and invasion of human SGC-7901 cells. Biochimie 2011, 93:954-961.
• [14]Ouban A, Ahmed AA: Claudins in human cancer: A review. Histol Histopathol 2010, 25:83-90.
• [15]Konecny GE, Agarwal R, Keeney GA, Winterhoff B, mariani A, Riehle D, Neuper C, Dowdy SC, Wang HJ, Morin PJ, Podratz KC: Caludin-3 and claudin-4 expression in serous papillary, clear-cell, and endometrioid endometrial cancer. Gynecol Oncol 2008, 109:263-269.
• [16]Kiss A, Schaff Z, Sobel G: Claudins as diagnostic and prognostic markers in gynecological cancer. Histol Histopathol 2009, 24:1607-1615.
• [17]Nakayama F, Semba S, Usami Y, Chiba H, Sawada N, Yokozaki H: Hypermethylation-modulated downregulation of claudin-7 expression promotes the progression of colorectal carcinoma. Pathobiology 2008, 75:177-185.
• [18]Szasz AM, Tokes AM, Micsinai M, Krenacs T, Jakab C, Lukacs L, Nemeth Z, Baranyai Z, Dede K, Madaras L, Kulka J: Prognostic significance of claudin expression changes in breast cancer with regional lymph node metastasis. Clin Exp Metastasis 2011, 28:55-63.
• [19]Lourenco SV, Coutinho-Camillo CM, Buim ME, Pereira CM, Carvalho AL, kowalski LP, Soares FA: Oral squamous cell carcinoma: status of tight junction claudins in the different histopathological patterns and relationship with clinical parameters. A tissue-microarray-based study of 136 cases. J Clin Pathol 2010, 63:609-614.
• [20]Creasman WT: Revision in classification by International Federation of Gynecology and Obstetrics. Am J Obstet Gynecol 1992, 167:857-858.
• [21]Pan XY, Wang B, Che YC, Weng ZP, Dai HY, Peng W: expression of claudin-3 and claudin-4 in normal, hyperplastic, and malignant endometrial tissue. Int j Gynecol Cancer 2007, 17:233-241.
• [22]Santin AD, Bellone S, Marizzoni M, Palmieri M, Seigel ER, McKenney JK, Hennings L, Comper F, Bandiera E, Pecorelli S: Overexpression of claudin-3 and claudin-4 receptors in uterine serous papillary carcinoma: novel targets for a type-specific therapy using clostriduim perfringens enterotoxin (CPE). Cancer 2007, 109:1312-1322.
• [23]Santin AD, Zhan F, Cane' S, Bellone S, Palmieri M, Thomas M, Burnett A, Roman JJ, Cannon MJ, Shaughnessy J Jr, Pecorelli S: Gene expression fingerprint of uterine serous papillary carcinomas: identification of novel molecular markers of uterine serous cancer diagnosis and therapy. Br J Cancer 2005, 92:1561-1573.
• [24]Ohtani K, Sakamoto H, Rutherford T, Chen Z, Kikucji A, Yamamoto T, Satoh K, Naftolin F: Ezrin, a membrane-cytoskeletal linking protein, is highly expressed in atypical endometrial hyperplasia and uterine endometrioid adenocarcinoma. Cancer Lett 2002, 179:79-86.
• [25]Ohtani K, Sakamoto H, Rutherford T, Chen Z, Satoh K, Naftolin F: Ezrin, a membrane-cytoskeletal linking protein, is involved in the process of invasion of endometrial cancer cells. Cancer Lett 1999, 147:31-38.
• [26]Kobel M, Langhammer T, Huttelmaier S, Scmitt WD, Kriese K, Dittmer J, Strauss H-G, Thomssen C, Hauptmann S: Ezrin expression is related to poor prognosis in FIGO I endometrioid carcinomas. Mod Pathol 2006, 19:581-587.
• [27]Tokunou M, Niki T, Saitoh Y, Imamura H, Sakamoto M, Hirohashi S: Altered expression of the ERM proteins in lung adenocarcinoma. Lab Invest 2000, 80:1643-1650.
• [28]Kobayashi H, Sagara J, Kurita H, Morifuji M, Ohishi M, Kurashina K, Taniguchi A: Clincial significance of cellular distribution of moesin in patients with oral squamous cell carcinoma. Clin Cancer Res 2004, 10:572-580.